ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Adoptive Transfer of ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) in Combination With Lymphodepletion and Anti-PD-1 to Patients With Metastatic Melanoma
Sponsor: Inge Marie Svane
Terminated
Evaluation of step A did not support addition of pembrolizumab in step B
Other terminated trials from Inge Marie Svane
A PHASE1 clinical study on Malignant Melanoma, this trial is terminated or withdrawn. The trial is conducted by Inge Marie Svane and has accumulated 7 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Aug 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Aug 2025 [monthly]
Terminated PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Inge Marie Svane
- Technical University of Denmark
For direct contact, visit the study record on ClinicalTrials.gov .